Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28644942 | 0.79 | ALDH1A1 (0.62) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL3225396 | 0.77 | NOTUM (0.54) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17148998 | 0.76 | NOTUM (0.48) | NOTUMMAPK1LPLLIPG | |
| SCHEMBL20904636 | 0.75 | LIPG (0.62) | LPLLIPG | |
| SCHEMBL1016421 | 0.75 | NOTUM (0.51) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL22325380 | 0.74 | HPGD (0.49) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL13466833 | 0.74 | NOTUM (0.47) | NOTUMALDH1A1HPGDMAPK1MAPT | |
| SCHEMBL22035758 | 0.74 | LIPG (0.57) | LPLLIPG | |
| SCHEMBL21147241 | 0.74 | LIPG (0.57) | LPLLIPG | |
| SCHEMBL17148999 | 0.73 | NOTUM (0.48) | NOTUMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908824-B1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9416129-B2 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416129-B2 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | NOTUM 1404/4885ALDH1A1 734/4885HPGD 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.